Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P plus Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC)

被引：0
|
作者：
Kapoun, A. [1 ]
O'Reilly, E. [2 ]
Cohn, A. [3 ]
Bendell, J. C. [4 ]
Smith, L. [5 ]
Strickler, J. H. [6 ]
Gluck, W. [7 ]
Liu, Y. W. [1 ]
Wallace, B. [1 ]
Tam, R. [1 ]
Cancilla, B. [1 ]
Brunner, A. [1 ]
Hill, D. [1 ]
Zhou, L. [1 ]
Dupont, J. [1 ]
Zhang, C. [1 ]
Wang, M. [1 ]
机构：
[1] OncoMed Pharmaceut, Davis, CA USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Rocky Mt Canc Ctr, Denver, CO USA
[4] Sarah Canon Res Inst, Nashville, TN USA
[5] START, San Antonio, TX USA
[6] Duke Univ, Durham, NC USA
[7] Greenville Hosp Syst, Greenville, SC USA
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70591-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
465
引用
收藏
页码：152 / 152
页数：1
相关论文
共 50 条
  • [1] A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC)
    Shen, Lin
    Yu, Xianjun
    Hao, Jihui
    Wang, Liwei
    Pan, Hongming
    Han, Guohong
    Xu, Jian-Ming
    Zhang, Yanqiao
    Yang, Shujun
    Chen, Jia
    Ying, Jieer
    Dai, Guanghai
    Li, Mingyu
    Begic, Damir
    Lu, Brian D.
    Xu, Ruihua
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [2] Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P plus Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC)
    O'Reilly, Eileen Mary
    Smith, Lon S.
    Bendell, Johanna C.
    Rangwala, Fatima A.
    Schmidt, William
    Stephenson, Joe
    Kapoun, Ann
    Xu, Lu
    Hill, Dawn
    Zhou, Lei
    Dupont, Jakob
    Cohn, Allen Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [3] Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P plus Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).
    O'Reilly, Eileen Mary
    Smith, Lon S.
    Bendell, Johanna C.
    Strickler, John H.
    Zalupski, Mark
    Gluck, William
    Kapoun, Ann
    Yen, Wan-Ching
    Xu, Lu
    Hill, Dawn
    Zhou, Lei
    Dupont, Jakob
    Cohn, Allen Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [4] Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).
    Goldstein, David
    Von Hoff, Daniel D.
    Chiorean, E. Gabriela
    Reni, Michele
    Tabernero, Josep
    Ramanathan, Ramesh K.
    Aly, Abdalla
    Botteman, Marc
    Wilkersen, Julia
    Margunato-Debay, Sandra
    Lu, Brian
    Louis, Chrystal Ursula
    Renschler, Markus Frederic
    McGovern, Desmond Micahel Thomas
    Lee, Chee Khoon
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P plus Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).
    O'Reilly, Eileen Mary
    Sahai, Vaibhav
    Bendell, Johanna C.
    Bullock, Andrea J.
    LoConte, Noelle K.
    Hatoum, Hassan
    Ritch, Paul S.
    Hool, Hugo
    Leach, Joseph W.
    Sanchez, James
    Sohal, Davendra
    Strickler, John H.
    Patel, Ravindranath
    Wang-Gillam, Andrea
    Firdaus, Irfan
    Kapoun, Ann M.
    Holmgren, Eric
    Zhou, Lei
    Dupont, Jakob
    Picozzi, Vincent J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [6] A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) plus /- nab-paclitaxel in patients with pancreatic cancer.
    Hidalgo, Manuel
    Cooray, Prasad
    Carrato, Alfredo
    Jameson, Michael B.
    Parnis, Francis
    Jeffery, Mark
    Grimison, Peter S.
    Stagg, Robert J.
    Holmgren, Eric
    Kapoun, Ann M.
    Dupont, Jakob
    Tebbutt, Niall C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [7] Efficacy and safety of nab-Paclitaxel (nab-P) plus gemcitabine (Gem) vs gem alone in patients (Pts) with metastatic pancreatic cancer (MPC) treated to progressive disease (PD) in the phase III MPACT trial
    Vogel, A.
    Penenberg, D.
    McGovern, D.
    Romano, A.
    Michael, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S455 - S455
  • [8] Phase III study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with metastatic pancreatic adenocarcinoma (mPC): Subgroup analysis of Canadian pts from the MPACT trial
    Tehfe, Mustapha Ali
    Dowden, Scot D.
    Kennecke, Hagen F.
    El-Maraghi, Robert Hassan
    Lesperance, Bernard
    Couture, Felix
    Letourneau, Richard
    Penenberg, Darryl Neil
    Romano, Alfredo
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [9] Efficacy and safety of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in Chinese patients (Pts) with metastatic adenocarcinoma of the pancreas (MPC): A phase II study
    Yu, X.
    Shen, L.
    Hao, J.
    Wang, L.
    Pan, H.
    Han, G.
    Xu, J.
    Zhang, Y.
    Yang, S.
    Ying, J.
    Li, M.
    Begic, D.
    Lu, B.
    Xu, R.
    ANNALS OF ONCOLOGY, 2015, 26 : 66 - 67
  • [10] Phase 1B trial of ADI-PEG 20 (A) plus nab-Paclitaxel (nab-P) and gemcitabine (gem) in subjects with advanced pancreatic cancer (APC).
    Lowery, Maeve Aine
    Capanu, Marinela
    Glassman, Danielle C.
    Covington, Christina M.
    Gluskin, Jill
    Brenner, Robin
    Li, Chien-Feng
    Bomalaski, John S.
    Johnston, Amanda
    Barba, Adalberto
    Yu, Kenneth H.
    Kelsen, David Paul
    Abou-Alfa, Ghassan K.
    Saltz, Leonard
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345